|Alemtuzumab||Alendronic Acid||Aleuritic Acid||Alexidine||Alexitol Sodium|
|Systematic (IUPAC) name|
|1-92-LFA-3 (Antigen) (human) fusion protein with immunoglobin G1 (human hinge CH2-CH3γ1-chain) dimer|
|Pregnancy cat.||C (AU) B (US)|
|Legal status||℞-only (US)|
|Mol. mass||51801.1 g/mol|
|(what is this?)|
Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 2011, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US, Inc. (http://www.amevive.com/Patient%20letter.pdf), the decision to cease Amevive sales was neither the result of any specific safety concern nor the result of any FDA-mandated or voluntary product recall. On the other hand, usage of Amevive was associated with a certain risk of development systemic diseases such as malignancies. This drug was never approved for the European drug market.
Alefacept is used to control inflammation in moderate to severe psoriasis with plaque formation, where it interferes with lymphocyte activation. It is also being studied in the treatment of cutaneous T-cell lymphoma and T-cell non-Hodgkin lymphoma.
Alefacept is a fusion protein: it combines part of an antibody with a protein that blocks the growth of some types of T cells.